Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GAO and nutritionals

This article was originally published in The Tan Sheet

Executive Summary

Report examining existing federal mechanisms for ensuring the safety of supplements and functional foods and the accuracy of their labeling/advertising claims is slated for July release. The analysis, a self-initiated project by the General Accounting Office, was spurred by consumer interest and growth in the industry. The analysis will incorporate data from approximately two dozen entities, including FDA, NIH, FTC, the California Department of Health, trade groups, nutrition and consumer groups, academia and six food companies. GAO's August 1999 report questioning FDA's reliance on AER data to support a proposed rule restricting the use of ephedrine alkaloids in supplements was a key factor in the agency's recent withdrawal of the proposed reg's dosing and duration of use limits (1"The Tan Sheet" March 6, p. 9)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091182

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel